Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Sacituzumab Tirumotecan”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT07318558
What this trial is testing

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

Who this might be right for
Ovarian NeoplasmsOvarian Cancer
Merck Sharp & Dohme LLC 900
Testing effectiveness (Phase 2)Looking for participantsNCT07323056
What this trial is testing

Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer

Who this might be right for
EGFR-mutant Non-small Cell Lung CancerPotentially Resectable
Shanghai Pulmonary Hospital, Shanghai, China 36
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07193160
What this trial is testing

Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)
Fudan University 45
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07689292
What this trial is testing

Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction (GEJ) AdenocarcinomaGastro-esophageal Junction Adenocarcinoma
Tianjin Medical University Cancer Institute and Hospital 45
Large-scale testing (Phase 3)Active Not RecruitingNCT06356311
What this trial is testing

Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

Who this might be right for
Gastroesophageal Cancer
Merck Sharp & Dohme LLC 450
Testing effectiveness (Phase 2)Active Not RecruitingNCT07703228
What this trial is testing

Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLC

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)NSCLC Stage IIIB~IVSecond-line Therapy+1 more
Nanfang Hospital, Southern Medical University 38
Large-scale testing (Phase 3)Looking for participantsNCT06170788
What this trial is testing

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC 614
Large-scale testing (Phase 3)Active Not RecruitingNCT06305754
What this trial is testing

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC 550
Early research (Phase 1)Not Yet RecruitingNCT07702305
What this trial is testing

Safety and Efficacy of Intrathecal Sacituzumab Tirumotecan for Leptomeningeal Metastasis in EGFR-TKI-Resistant Non-Small Cell Lung Cancer

Who this might be right for
EGFR-TKI-resistant Non-small Cell Lung Cancer With Leptomeningeal Metastasis
Henan Cancer Hospital 15
Large-scale testing (Phase 3)Active Not RecruitingNCT06132958
What this trial is testing

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

Who this might be right for
Endometrial Cancer
Merck Sharp & Dohme LLC 710
Large-scale testing (Phase 3)Active Not RecruitingNCT06074588
What this trial is testing

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC 556
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07343479
What this trial is testing

Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)EGFR Gene MutationsBrain Metastasis
Zhejiang Cancer Hospital 45
Testing effectiveness (Phase 2)Looking for participantsNCT07438626
What this trial is testing

Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma

Who this might be right for
Phase IISacituzumabTirumotecan+1 more
M.D. Anderson Cancer Center 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07244874
What this trial is testing

Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC

Who this might be right for
TNBC - Triple-Negative Breast CancerPD-L1 Positive
Tianjin Medical University Cancer Institute and Hospital 41
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07197008
What this trial is testing

Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain Metastasis

Who this might be right for
Lung Cancer
Li-kun Chen 50
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07054242
What this trial is testing

A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)

Who this might be right for
Neoadjuvant TherapyStage II to III (T1cN1-2 or T2-4N0-2) TNBC Breast Cancer
Yantai Yuhuangding Hospital 52
Large-scale testing (Phase 3)Looking for participantsNCT06841354
What this trial is testing

Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Who this might be right for
Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC 1,000
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07561463
What this trial is testing

Sacituzumab Tirumotecan for Pancreatic Cancer

Who this might be right for
Pancreatic Ductal Adenocarcinoma (PDAC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 30
Large-scale testing (Phase 3)Looking for participantsNCT06422143
What this trial is testing

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

Who this might be right for
Non-small Cell Lung CancerNSCLC
Merck Sharp & Dohme LLC 851
Testing effectiveness (Phase 2)Looking for participantsNCT07179783
What this trial is testing

Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)

Who this might be right for
Prostate Cancer (Adenocarcinoma)Prostate Cancer Metastatic Castration-ResistantProstate Adenocarcinoma With Neuroendocrine Differentiation
Tianjin Medical University Second Hospital 28
Next Page